Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.65 |
| ▸ | THRB | P10828 | 1/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.65 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.60 |
| ▸ | ATM | Q13315 | 2/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | GLA | P06280 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | ANPEP | P15144 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29628052 | 0.99 | ALDH1A1 (0.64) | ALDH1A1CYP2C9CYP2C19THRBHSD17B10 | |
| Trifluoroacetic Acid SCHEMBL29484051 | 0.94 | ALDH1A1 (0.58) | ALDH1A1CYP2C9CYP2C19THRBHSD17B10 | |
| SCHEMBL30581396 | 0.92 | OPRK1 (0.69) | ALDH1A1CYP2C9CYP2C19THRBHSD17B10 | |
| SCHEMBL28231245 | 0.92 | OPRK1 (0.69) | ALDH1A1CYP2C9CYP2C19THRBHSD17B10 | |
| SCHEMBL7139809 | 0.92 | OPRK1 (0.69) | ALDH1A1CYP2C9CYP2C19THRBHSD17B10 | |
| SCHEMBL30581395 | 0.92 | OPRK1 (0.69) | ALDH1A1CYP2C9CYP2C19THRBHSD17B10 | |
| Hydrochloric Acid SCHEMBL29661828 | 0.90 | OPRK1 (0.67) | ALDH1A1CYP2C9CYP2C19THRBHSD17B10 | |
| Bromide SCHEMBL11571243 | 0.90 | OPRK1 (0.67) | ALDH1A1CYP2C9CYP2C19THRBHSD17B10 | |
| SCHEMBL2739539 | 0.89 | BIRC2 (0.59) | ALDH1A1CYP2C9CYP2C19THRBHSD17B10 | |
| SCHEMBL8212986 | 0.89 | ALDH1A1 (0.73) | ALDH1A1CYP2C9CYP2C19THRBHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612429-B2 | Derivatives of dolaproine-dolaisoleuine peptides | AGENSYS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-20250064964-A1 | ANTIBODY DRUG CONJUGATES FOR ABLATING HEMATOPOIETIC STEM CELLS | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC. DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION (GNF) | 2025-02-27 | — | — | US | disclosed |
| US-12171839-B2 | Antibody drug conjugates for ablating hematopoietic stem cells | NOVARTIS AG (CH) | 2024-12-24 | — | — | US | disclosed |
| CN-117653740-A | Antibody drug conjugates for ablating hematopoietic stem cells | 诺华股份有限公司 | 2024-03-08 | — | — | CN | disclosed |
| CN-110099697-B | Antibody drug conjugates for ablating hematopoietic stem cells | 诺华股份有限公司 | 2023-11-28 | — | — | CN | disclosed |
| US-20230129674-A1 | EFFICIENT PREPARATION OF DOLASTATIN AND AURISTATIN ANALOGS THROUGH A COMMON INTERMEDIATE | SIGMA-ALDRICH CO. LLC | 2023-04-27 | — | — | US | disclosed |
| EP-4118094-A1 | EFFICIENT PREPARATION OF DOLASTATIN AND AURISTATIN ANALOGS THROUGH A COMMON INTERMEDIATE | Sigma-Aldrich Co. LLC (US) | 2023-01-18 | — | — | EP | disclosed |
| CN-115190882-A | Efficient preparation of dolastatin and auristatin analogs via common intermediates | 西格马-奥尔德里奇有限责任公司 | 2022-10-14 | — | — | CN | disclosed |
| US-20220305134-A1 | ANTIBODY DRUG CONJUGATES FOR ABLATING HEMATOPOIETIC STEM CELLS | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC. DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION (GNF) | 2022-09-29 | — | — | US | disclosed |
| US-20220204557-A1 | DERIVATIVES OF DOLAPROINE-DOLAISOLEUINE PEPTIDES | AGENSYS, INC. (US) | 2022-06-30 | — | — | US | disclosed |
| US-11357864-B2 | Antibody drug conjugates for ablating hematopoietic stem cells | NOVARTIS AG (CH) | 2022-06-14 | — | — | US | disclosed |
| US-11312748-B2 | Derivatives of dolaproine-dolaisoleucine peptides | AGENSYS, INC. (US) | 2022-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250064964-A1 | ANTIBODY DRUG CONJUGATES FOR ABLATING HEMATOPOIETIC STEM CELLS | ABL1, BCR, CD47 | ALDH1A1 205/4885CYP2C9 1235/4885CYP2C19 1222/4885 |
| US-20220204557-A1 | DERIVATIVES OF DOLAPROINE-DOLAISOLEUINE PEPTIDES | DDOST, VIP, THPO | ALDH1A1 4511/4885CYP2C9 3715/4885CYP2C19 2321/4885 |
| US-20220305134-A1 | ANTIBODY DRUG CONJUGATES FOR ABLATING HEMATOPOIETIC STEM CELLS | BCR, ABL1, CD47 | ALDH1A1 167/4885CYP2C9 1576/4885CYP2C19 1582/4885 |
| US-12612429-B2 | Derivatives of dolaproine-dolaisoleuine peptides | DDOST, NGLY1, GRPR | ALDH1A1 3977/4885CYP2C9 3984/4885CYP2C19 3809/4885 |
| US-20230129674-A1 | EFFICIENT PREPARATION OF DOLASTATIN AND AURISTATIN ANALOGS THROUGH A COMMON INTERMEDIATE | AURKC, AURKA, AURKB | ALDH1A1 2108/4885CYP2C9 2789/4885CYP2C19 2527/4885 |
| US-11312748-B2 | Derivatives of dolaproine-dolaisoleucine peptides | VIP, DDOST, DNPEP | ALDH1A1 4599/4885CYP2C9 4259/4885CYP2C19 3613/4885 |
| US-11357864-B2 | Antibody drug conjugates for ablating hematopoietic stem cells | BCR, ABL1, CD47 | ALDH1A1 167/4885CYP2C9 1576/4885CYP2C19 1582/4885 |
| US-12171839-B2 | Antibody drug conjugates for ablating hematopoietic stem cells | BCR, ABL1, CD47 | ALDH1A1 167/4885CYP2C9 1576/4885CYP2C19 1582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.